Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas.

Abstract:

:The prognosis remains ill-defined in patients with liver metastases of well-differentiated (WD) digestive endocrine carcinomas (DEC) with high Ki-67 index. The objectives of this study were to determine whether Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with DEC, and whether chemotherapy commonly used in patients with poorly differentiated (PD) carcinomas might be applied to those with high Ki-67 index but well-differentiated DEC. Sixty-three patients with DEC metastatic to the liver were retrospectively studied and divided into three prognostic groups. Group 1 comprised patients with well-differentiated carcinomas and Ki-67 index<15% (n=28), group 2 comprised those with well-differentiated carcinomas and Ki-67 index≥15% (n=17), and group 3 comprised those with poorly differentiated carcinomas (n=18). Therapeutic strategy was decided in accordance to guidelines, and tumoral response rate was assessed by computed tomography scan (RECIST). Prognostic factors were determined by uni/multivariate analysis. The 5-year survival rates were 89, 36, and 6% in groups 1, 2, and 3 respectively (P<0.001). Multivariate analysis showed that Ki-67 index≥15%, poor tumor differentiation, and large liver tumor burden were independent predictors of poorer survival. Disease control rates after etoposide-cisplatin were 50 and 53% in groups 2 and 3 respectively (NS). In conclusion, Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of DEC. Patients with well-differentiated carcinomas with high Ki-67 index (≥15%) have intermediate prognosis and a similar response rate to the etoposide-cisplatin combination as those with poorly differentiated carcinomas.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Hentic O,Couvelard A,Rebours V,Zappa M,Dokmak S,Hammel P,Maire F,O'Toole D,Lévy P,Sauvanet A,Ruszniewski P

doi

10.1677/ERC-09-0319

subject

Has Abstract

pub_date

2010-12-13 00:00:00

pages

51-9

issue

1

eissn

1351-0088

issn

1479-6821

pii

ERC-09-0319

journal_volume

18

pub_type

杂志文章
  • Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers.

    abstract::Dendritic cells (DCs) are highly efficient antigen-presenting cells in the immune system with the potential to regulate the system and induce a cytotoxic T-cell response. As a proof of principle, a multitude of animal and human studies has demonstrated that immunization with antigen-loaded DCs may lead to anti-tumour ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.1.01133

    authors: Schott M

    更新日期:2006-09-01 00:00:00

  • Inhibition of Notch signaling attenuates pituitary adenoma growth in Nude mice.

    abstract::Preclinical and clinical studies support that Notch signaling may play an important oncogenic role in cancer, but there is scarce information for pituitary tumors. We therefore undertook a functional study to evaluate Notch participation in pituitary adenoma growth. Tumors generated in Nude mice by subcutaneous GH3 so...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0337

    authors: Zubeldía-Brenner L,De Winne C,Perrone S,Rodríguez-Seguí SA,Willems C,Ornstein AM,Lacau-Mengido I,Vankelecom H,Cristina C,Becu-Villalobos D

    更新日期:2019-01-01 00:00:00

  • Differential sensitivities to lactate transport inhibitors of breast cancer cell lines.

    abstract::The tumour microenvironment is known to be acidic due to high glycolytic rates of tumour cells. Monocarboxylate transporters (MCTs) play a role in extracellular acidification, which is widely known to be involved in tumour progression. Recently, we have described the upregulation of MCT1 in breast carcinomas and its a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-13-0132

    authors: Morais-Santos F,Miranda-Gonçalves V,Pinheiro S,Vieira AF,Paredes J,Schmitt FC,Baltazar F,Pinheiro C

    更新日期:2013-12-16 00:00:00

  • A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping.

    abstract::Selection of novel molecular markers is an important goal of cancer genomics studies. The aim of our analysis was to apply the multivariate bioinformatical tools to rank the genes - potential markers of papillary thyroid cancer (PTC) according to their diagnostic usefulness. We also assessed the accuracy of benign/mal...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-06-0048

    authors: Fujarewicz K,Jarzab M,Eszlinger M,Krohn K,Paschke R,Oczko-Wojciechowska M,Wiench M,Kukulska A,Jarzab B,Swierniak A

    更新日期:2007-09-01 00:00:00

  • Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.

    abstract::Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such as papillary and follicular cancers, which have survival rates of approximately 95% at 40 years. However, 15-20% of cases became radioi...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0555

    authors: Viola D,Valerio L,Molinaro E,Agate L,Bottici V,Biagini A,Lorusso L,Cappagli V,Pieruzzi L,Giani C,Sabini E,Passannati P,Puleo L,Matrone A,Pontillo-Contillo B,Battaglia V,Mazzeo S,Vitti P,Elisei R

    更新日期:2016-04-01 00:00:00

  • Targeting muscle signaling pathways to minimize adverse effects of androgen deprivation.

    abstract::Androgen deprivation therapy (ADT) is a highly effective treatment used in ∼30% of men with prostate cancer. Adverse effects of ADT on muscle are significant with consistent losses in muscle mass. However, effects of ADT on muscle strength and physical function, of most relevance to the patient, are less well understo...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0232

    authors: de Rooy C,Grossmann M,Zajac JD,Cheung AS

    更新日期:2016-01-01 00:00:00

  • Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells.

    abstract::The HIV protease inhibitor Nelfinavir (NFV) inhibits PI3K/AKT and MAPK/ERK signaling pathways, emerging targets in thyroid cancers. We examined the effects of NFV on cancer cells that derived from follicular (FTC), papillary (PTC) and anaplastic (ATC) thyroid cancers. NFV (1-20 µM) was tested in FTC133, BCPAP and SW17...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0568

    authors: Jensen K,Bikas A,Patel A,Kushchayeva Y,Costello J,McDaniel D,Burman K,Vasko V

    更新日期:2017-03-01 00:00:00

  • Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer.

    abstract::The anaplastic lymphoma kinase (ALK) gene is frequently rearranged in various types of cancer and is highly responsive to targeted therapeutics. We developed a system to detect rearrangement of ALK in a large group of Korean thyroid cancer patients. We screened 474 malignant or benign thyroid tumor cases to identify A...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0467

    authors: Park G,Kim TH,Lee HO,Lim JA,Won JK,Min HS,Lee KE,Park DJ,Park YJ,Park WY

    更新日期:2015-02-01 00:00:00

  • Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.

    abstract::It has been proposed that knowledge of estrogen receptor beta (ER-beta) expression may refine estrogen receptor alpha (ER-alpha) predictivity of response to endocrine therapy. We challenged this hypothesis in ER-alpha-positive breast cancers subjected to preoperative antiestrogen treatment. Forty-seven elderly (> or =...

    journal_title:Endocrine-related cancer

    pub_type: 临床试验,杂志文章

    doi:10.1677/erc.1.00822

    authors: Cappelletti V,Celio L,Bajetta E,Allevi A,Longarini R,Miodini P,Villa R,Fabbri A,Mariani L,Giovanazzi R,Galante E,Greco M,Grazia Daidone M

    更新日期:2004-12-01 00:00:00

  • Current mouse and cell models in prostate cancer research.

    abstract::Mouse models of prostate cancer (PCa) are critical for understanding the biology of PCa initiation, progression, and treatment modalities. Here, we summarize recent advances in PCa mouse models that led to new insights into specific gene functions in PCa. For example, the study of transgenic mice with TMPRSS2/ERG, an ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0285

    authors: Wu X,Gong S,Roy-Burman P,Lee P,Culig Z

    更新日期:2013-06-24 00:00:00

  • The LRIG family: enigmatic regulators of growth factor receptor signaling.

    abstract::The leucine-rich repeats and immunoglobulin-like domains (LRIG) family of transmembrane proteins contains three vertebrate members (LRIG1, LRIG2 and LRIG3) and one member each in flies (Lambik) and worms (Sma-10). LRIGs have stepped into the spotlight as essential regulators of growth factor receptors, including recep...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-14-0179

    authors: Simion C,Cedano-Prieto ME,Sweeney C

    更新日期:2014-01-01 00:00:00

  • The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

    abstract::Ovarian cancer remains one of the leading causes of cancer deaths. Thus, new biomarkers predictive of response to the standard paclitaxel-carboplatin treatment are needed to improve chemotherapy strategies. MicroRNAs have the potential to modify drug outcomes. Based on this, we have demonstrated in this study that pat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-10-0148

    authors: Leskelä S,Leandro-García LJ,Mendiola M,Barriuso J,Inglada-Pérez L,Muñoz I,Martínez-Delgado B,Redondo A,de Santiago J,Robledo M,Hardisson D,Rodríguez-Antona C

    更新日期:2010-12-21 00:00:00

  • PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A.

    abstract::Genetic variants in components of the protein kinase A (PKA) enzyme have been associated with various defects and neoplasms in the context of Carney complex (CNC) and in isolated cases, such as in primary pigmented nodular adrenocortical disease (PPNAD), cortisol-producing adrenal adenomas (CPAs), and various cancers....

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0309

    authors: Espiard S,Drougat L,Settas N,Haydar S,Bathon K,London E,Levy I,Faucz FR,Calebiro D,Bertherat J,Li D,Levine MA,Stratakis CA

    更新日期:2020-11-01 00:00:00

  • Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.

    abstract::Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumors of the adrenal glands and the sympathetic and parasympathetic paraganglia. They can occur sporadically or as a part of different hereditary tumor syndromes. About 30% of PCCs and PGLs are currently believed to be caused by germline mutat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-11-0170

    authors: Welander J,Söderkvist P,Gimm O

    更新日期:2011-12-01 00:00:00

  • Real-time, high-resolution imaging of tumor cells in genetically engineered and orthotopic models of thyroid cancer.

    abstract::Genetically engineered and orthotopic xenograft mouse models have been instrumental for increasing our understanding of thyroid cancer progression and for the development of novel therapeutic approaches in a setting that is more physiologically relevant than the classical subcutaneous flank implants. However, the anat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0295

    authors: Shanja-Grabarz X,Coste A,Entenberg D,Di Cristofano A

    更新日期:2020-10-01 00:00:00

  • 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.

    abstract::177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete responses are still uncomm...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0509

    authors: Hofving T,Sandblom V,Arvidsson Y,Shubbar E,Altiparmak G,Swanpalmer J,Almobarak B,Elf AK,Johanson V,Elias E,Kristiansson E,Forssell-Aronsson E,Nilsson O

    更新日期:2019-04-01 00:00:00

  • Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.

    abstract::The function of estrogen receptor beta (ER-beta) in mammary tissue is not completely understood. While early observations were often conflicting, more recent data suggest an important role as a tumor-suppressor gene. A decrease of ER-beta expression has been observed in ductal carcinoma in situ and invasive carcinoma ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01088

    authors: Rody A,Holtrich U,Solbach C,Kourtis K,von Minckwitz G,Engels K,Kissler S,Gätje R,Karn T,Kaufmann M

    更新日期:2005-12-01 00:00:00

  • Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.

    abstract::Autotaxin is a secreted enzyme that converts extracellular lysophosphatidylcholine to lysophosphatidate (LPA). In cancers, LPA increases tumour growth, metastasis and chemoresistance by activating six G-protein coupled receptors. We examined >200 human thyroid biopsies. Autotaxin expression in metastatic deposits and ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-15-0045

    authors: Benesch MG,Ko YM,Tang X,Dewald J,Lopez-Campistrous A,Zhao YY,Lai R,Curtis JM,Brindley DN,McMullen TP

    更新日期:2015-08-01 00:00:00

  • Multiple endocrine neoplasia type 1.

    abstract::Combined clinical and laboratory investigations of multiple endocrine neoplasia type 1 (MEN1) have resulted in an increased understanding of this disorder which may be inherited as an autosomal dominant condition. Defining the features of each disease manifestation in MEN1 has improved patient management and treatment...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060449

    authors: Pannett AA,Thakker RV

    更新日期:1999-12-01 00:00:00

  • Advances in paraganglioma-pheochromocytoma cell lines and xenografts.

    abstract::This review describes human and rodent-derived cell lines and xenografts developed over the last five decades that are suitable or potentially suitable models for paraganglioma-pheochromocytoma research. We outline the strengths and weaknesses of various models and emphasize the recurring theme that, despite the major...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0434

    authors: Bayley JP,Devilee P

    更新日期:2020-12-01 00:00:00

  • Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment.

    abstract::Because intracellular polyamines have a critical role in cell proliferation and death pathways, the polyamine metabolic pathway represents a potential target for intervention in cancers. A number of polyamine analogues have been identified that downregulate polyamine synthesis and enhance polyamine catabolism, thereby...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060069

    authors: Davidson NE,Hahm HA,McCloskey DE,Woster PM,Casero RA Jr

    更新日期:1999-03-01 00:00:00

  • Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.

    abstract::Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited treatment options. We explored novel treatment modalities by targeting epigenetic modifications using inhibitors of BET (e.g. BRD4) activity. We evaluated the efficacy in the treatment of ATC of a novel BET inhibitor, PLX51107 (PLX), currently in...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0107

    authors: Zhu X,Park S,Lee WK,Cheng SY

    更新日期:2019-09-01 00:00:00

  • Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation.

    abstract::Mutations of the aryl hydrocarbon receptor interacting protein (AIP) gene are associated with pituitary adenomas that usually occur as familial isolated pituitary adenomas (FIPA). Detailed pathological and tumor genetic data on AIP mutation-related pituitary adenomas are not sufficient. Non-identical twin females pres...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0059

    authors: Villa C,Lagonigro MS,Magri F,Koziak M,Jaffrain-Rea ML,Brauner R,Bouligand J,Junier MP,Di Rocco F,Sainte-Rose C,Beckers A,Roux FX,Daly AF,Chiovato L

    更新日期:2011-06-08 00:00:00

  • Support of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cells.

    abstract::The expression of estrogen receptor α (ERα) in breast cancer identifies patients most likely to respond to endocrine treatment. The second ER, ERβ, is also expressed in breast tumors, but its function and therapeutic potential need further study. Although in vitro studies have established that ERβ opposes transcriptio...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-13-0444

    authors: Jonsson P,Katchy A,Williams C

    更新日期:2014-01-30 00:00:00

  • The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs).

    abstract::Non-functioning pituitary adenomas, recently alternatively termed pituitary neuroendocrine tumours (NFpitNETs), are mostly benign neoplasms that are not associated with a hormonal hypersecretory syndrome. The clinical spectrum of NFpitNETs varies from completely asymptomatic to the development of panhypopituitarism an...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-20-0136

    authors: Yavropoulou MP,Tsoli M,Barkas K,Kaltsas G,Grossman A

    更新日期:2020-10-01 00:00:00

  • Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells.

    abstract::Chitinase 3-like 1 (CHI3L1 or YKL40) is a secreted glycoprotein highly expressed in tumours from patients with advanced stage cancers, including prostate cancer (PCa). The exact function of YKL40 is poorly understood, but it has been shown to play an important role in promoting tumour angiogenesis and metastasis. The ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0267

    authors: Jeet V,Tevz G,Lehman M,Hollier B,Nelson C

    更新日期:2014-10-01 00:00:00

  • Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer.

    abstract::Along with breast and endometrial cancers, thyroid cancer is a major component cancer in Cowden syndrome (CS). Germline variants in SDHB/C/D (SDHx) genes account for subsets of CS/CS-like cases, conferring a higher risk of breast and thyroid cancers over those with only germline PTEN mutations. To investigate whether ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0537

    authors: Ni Y,Seballos S,Ganapathi S,Gurin D,Fletcher B,Ngeow J,Nagy R,Kloos RT,Ringel MD,LaFramboise T,Eng C

    更新日期:2015-04-01 00:00:00

  • Androgens, diabetes and prostate cancer.

    abstract::Metabolic disorders such as diabetes, obesity and the metabolic syndrome have been shown to modulate prostate cancer (PCa) risk and aggressiveness in population-based and experimental studies. While associations between these conditions are modest and complex, two consistent findings have emerged. First, there is obse...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0067

    authors: Grossmann M,Wittert G

    更新日期:2012-09-05 00:00:00

  • Circulating microRNAs: macro-utility as markers of prostate cancer?

    abstract::The realization that microRNAs (miRNAs) are frequently deregulated in malignancy has had a major impact on cancer research. In particular, the recent finding that highly stable forms of miRNAs can be accurately measured in body fluids, including blood, has generated considerable excitement. Here, we discuss the potent...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0010

    authors: Selth LA,Tilley WD,Butler LM

    更新日期:2012-06-18 00:00:00

  • Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model.

    abstract::Anaplastic thyroid cancer is one of the most lethal diseases, and a curative therapy does not exist. Doxorubicin, the only drug approved for anaplastic thyroid cancer treatment, has a very low response rate and causes numerous side effects among which cardiotoxicity is the most prominent. Thus, doxorubicin delivery to...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0045

    authors: Marano F,Frairia R,Rinella L,Argenziano M,Bussolati B,Grange C,Mastrocola R,Castellano I,Berta L,Cavalli R,Catalano MG

    更新日期:2017-06-01 00:00:00